Pilulka Lékárny has completed an SPO on the START Market of the Prague Stock Exchange
Pilulka Lékárny, a.s. has completed an SPO on the START Market of the Prague Stock Exchange consisting of a capital increase through subscription of new shares. The funds will be used to further develop the company, particularly to strengthen its working capital, to bolster its activities in international markets and to further develop its own e-health solutions.
Since its foundation in 2013, Pilulka has emerged as a leading online pharmacy in central Europe and the operator of a network of franchise and select brick-and-mortar pharmacies in the Czech Republic. Pilulka operates in the Czech Republic, Slovakia and Romania, and entered the Austrian and Hungarian markets in 2022. Pilulka is the number one pharmacy e-shop in-home delivery in the Czech Republic and Slovakia, and among the top three retail pharmacy chains in the Czech Republic.
Oaklins’ team in the Czech Republic acted as an SPO manager in this transaction. The team succeeded in attracting orders from retail investors and high-net-worth individuals.
Talk to the deal team
Related deals
Kaviari has received a minority investment from idiCo
Kaviari has received a minority investment from a pool of investors led by idiCo, alongside Bpifrance, IRD Invest and UI Investissement.
Learn moreAWC has acquired a significant minority stake in MyFitness
AWC AS, the investment company of the Norwegian family office Awilhelmsen, has acquired a 22.2% stake in MyFitness AS, the largest fitness club operator in the Baltics, becoming the MyFitness’ largest single shareholder.
Learn moreInstituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn more